Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection.

Logge C, Vettorazzi E, Fischer L, Nashan B, Sterneck M.

Transpl Int. 2013 May;26(5):527-34. doi: 10.1111/tri.12085. Epub 2013 Mar 21.

2.

Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N.

Health Technol Assess. 2007 Mar;11(11):1-205, iii. Review.

3.

A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C.

Sagmeister M, Wong JB, Mullhaupt B, Renner EL.

Eur J Gastroenterol Hepatol. 2001 May;13(5):483-8. Review.

PMID:
11396525
4.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
5.

What is (cost) effective in patients with chronic hepatitis C virus infection?

Zeuzem S.

Eur J Gastroenterol Hepatol. 2001 May;13(5):473-6. Review.

PMID:
11396523
6.
7.

Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.

Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, Harris P, Price A.

Health Technol Assess. 2009 Jul;13(35):1-172, iii. doi: 10.3310/hta13350. Review.

8.

Advances in the treatment of hepatitis C.

Lawrence SP.

Adv Intern Med. 2000;45:65-105. Review.

PMID:
10635046
9.

Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C.

Townsend R, McEwan P, Kim R, Yuan Y.

Value Health. 2011 Dec;14(8):1068-77. doi: 10.1016/j.jval.2011.06.006. Epub 2011 Aug 27. Review.

10.

Treating hepatitis C in the prison population is cost-saving.

Tan JA, Joseph TA, Saab S.

Hepatology. 2008 Nov;48(5):1387-95. doi: 10.1002/hep.22509. Review.

PMID:
18924228
11.

The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C.

Bickerstaff C.

Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):787-800. doi: 10.1586/14737167.2015.1076337. Epub 2015 Aug 9. Review.

PMID:
26289734
12.
13.

Making it happen: managed care considerations in vanquishing hepatitis C.

McHutchison JG, Bacon BR, Owens GS.

Am J Manag Care. 2007 Dec;13 Suppl 12:S327-36; quiz S337-40. Review.

14.

Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C.

Tsochatzis EA, Crossan C, Longworth L, Gurusamy K, Rodriguez-Peralvarez M, Mantzoukis K, O'Brien J, Thalassinos E, Papastergiou V, Noel-Storr A, Davidson B, Burroughs AK.

Hepatology. 2014 Sep;60(3):832-43. doi: 10.1002/hep.27296. Epub 2014 Jul 29. Review.

15.

Cost-effectiveness of viral hepatitis B & C treatment.

Toy M.

Best Pract Res Clin Gastroenterol. 2013 Dec;27(6):973-85. doi: 10.1016/j.bpg.2013.08.020. Epub 2013 Sep 27. Review.

PMID:
24182615
16.

Outcomes research in chronic viral hepatitis C: effects of interferon therapy.

Bonkovsky HL, Woolley JM.

Can J Gastroenterol. 2000 Jul-Aug;14 Suppl B:21B-29B. Review.

PMID:
10938501
17.
18.

Finding Truth in a World Full of Spin: Myth-Busting in the Case of Sovaldi.

Schiff L.

Clin Ther. 2015 May 1;37(5):1092-112. doi: 10.1016/j.clinthera.2015.02.009. Epub 2015 Apr 4. Review.

PMID:
25850880
19.

Hepatitis C: An Eastern Perspective.

Dan YY, Lim SG.

Gastroenterol Clin North Am. 2015 Dec;44(4):793-805. doi: 10.1016/j.gtc.2015.07.007. Epub 2015 Sep 16. Review.

PMID:
26600220
20.

Hepatitis C: tackling the silent epidemic.

Hamlyn AN.

Br J Hosp Med (Lond). 2005 Oct;66(10):579-82. Review.

PMID:
16255265

Supplemental Content

Support Center